Found: 5
Select item for more details and to access through your institution.
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 3, p. 754, doi. 10.1111/dom.14280
- By:
- Publication type:
- Article
Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 3, p. 303, doi. 10.1111/dom.13896
- By:
- Publication type:
- Article
Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2019, v. 21, n. 10, p. 2315, doi. 10.1111/dom.13816
- By:
- Publication type:
- Article
1020-P: Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1020-P
- By:
- Publication type:
- Article
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article